Drug intelligence / Profile preview

SHP-PS2

Development stage: Unknown
Lead developer: Shandong University

Overview

SHP-PS2: sourced facts only. name: "SHP-PS2, the top-performing probe, exhibited an IC50 of 2.88 μmol/L against SHP2 and a Kd of 1.85 μmol/L in binding studies, with accurate SHP2 localization in living cells and tumor sections." [PMID:40168908]; target: "SHP-PS2, the top-performing probe, exhibited an IC50 of 2.88 μmol/L against SHP2 and a Kd of 1.85 μmol/L in binding studies, with accurate SHP2 localization in living cells and tumor sections." [PMID:40168908]; developer: "Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China." [PMID:40168908]

Targets

PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)

Beyond the preview

Go deeper on SHP-PS2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHP-PS2.